Objectives (1) To evaluate risk of hospitalization following initiation of perampanel (pre‐and
post‐analysis) and (2) to compare hospitalization rates following initiation of perampanel vs …

Objective To investigate whether newer anti-seizure medications (ASMs) are widely
prescribed for a range of adult patients in Japan, including patients with previously and …

Rationale Lacosamide (LCM) was initially approved in Taiwan in March 2014 for use as
adjunctive therapy for focal impaired awareness seizures and secondarily generalized …

Objective We evaluated the impact of planned dose reduction and mechanism of action of
concomitant AEDs on tolerability in adults with partial-onset seizures undergoing …

This noninterventional, observational, postauthorization safety study (SP0942,
NCT00771927) evaluated the incidence of predefined cardiovascular-(CV) and psychiatric …

Objective A large‐scale, double‐blind trial (SP0993; NCT01243177) demonstrated that
lacosamide was noninferior to controlled‐release carbamazepine (carbamazepine‐CR) in …

Objective To assess long‐term use and safety of lacosamide (LCM)≤ 800 mg/day
monotherapy in patients with partial‐onset seizures (POS) enrolled previously in a historical …

Objective The objective of this study was to describe a priori protocol-defined analyses to
evaluate the safety and tolerability of adjunctive oral lacosamide (200–600 mg/day) in adults …

Abstract Purpose Lacosamide (LCM), the R-enantiomer of 2-acetamido-N-benzyl-3-
methoxypropionamide, is a newer approved antiseizure medication characterized by a …

Objective Historically, approximately half of those with newly diagnosed epilepsy have
responded to and tolerated the first antiseizure medication (ASM), but there are few …